Discounted Cash Flow
Iovance Biotherapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $0 | $-52.9m | $-34.2m | — | $-1.85 |
| 2017 | $0 | $-92.1m (-74.1%) | $-79.7m (-133.2%) | — | $-1.41 (23.8%) |
| 2018 | $0 | $-123.6m (-34.2%) | $-102.4m (-28.5%) | — | $-1.27 (9.9%) |
| 2019 | — | $-197.6m (-59.9%) | $-165.8m (-61.8%) | — | $-1.59 (-25.2%) |
| 2020 | — | $-259.6m (-31.4%) | $-251.9m (-51.9%) | — | $-1.88 (-18.2%) |
| 2021 | — | $-342.3m (-31.8%) | $-265.5m (-5.4%) | — | $-2.23 (-18.6%) |
| 2022 | — | $-395.9m (-15.7%) | $-313.2m (-18.0%) | — | $-2.49 (-11.7%) |
| 2023 | $1.2m | $-444.0m (-12.2%) | $-384.1m (-22.6%) | -37345.4% | $-1.89 (24.1%) |
| 2024 | $164.1m (13699.0%) | $-372.2m (16.2%) | $-364.0m (5.2%) | -226.8% (99.4%) | $-1.28 (32.3%) |
| 2025 | $263.5m (60.6%) | $-391.0m (-5.1%) | $-336.2m (7.6%) | -148.4% (34.6%) | $-1.09 (14.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.